Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food ...

TLX007-CDx was approved by the FDA for PSMA-PET scanning in adult male patients with prostate cancer with suspected ...

The FDA has approved the use of Gozellix, a PSMA-PET imaging agent, to help detect prostate cancer using gallium-68 ...

MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ...

Fusion biopsy and patient follow-up with 3D mapping are the cornerstone of a successful Focal Therapy program. In line with ...

TLX007-CDx is a cold kit designed for the preparation of PSMA-targeted PET imaging for prostate cancer. It leverages ...

Brazil's health regulators have approved Telix Pharmaceuticals' nuclear imaging agent for prostate cancer, Illucix. ... Read ...

PSMA-PET imaging technology is leveraged to identify advanced prostate cancer. Credit: Korawat photo shoot / Shutterstock. Brazilian Health Regulatory Agency (ANVISA) has granted approval for Telix ...

The PSMA-PET imaging agent will be used for patients who have suspected metastasis and those with suspected cancer recurrence.

A new at-home saliva test could help identify men with a high risk of prostate cancer more accurately than blood tests, ...

Through its vast network of top urologists, oncologists, and researchers from world-class institutions, Human Longevity's $1 ...